AstraZeneca’s obesity drug shows promise as analysts see upside beyond consensus
AstraZeneca is emerging as a potential new contender in the booming obesity treatment market after its experimental weight-loss pill delivered encouraging mid-stage trial results, prompting investors and analysts to reassess whether the British drugmaker can challenge the dominance of Novo Nordisk and Eli Lilly. The company said on Monday that patients receiving the highest dose
